Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
| Market Capitalization | $61.3051 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | 0 |
| Book Value | 0.015 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.02 |
| EBITDA | -11,752.426 |
| Profit Margin | 0 |
| Operating Margin TTM | -7.447 |
| Return on Assets TTM | -0.4169 |
| Return on Equity TTM | -0.7314 |
| Revenue TTM | 1,579.849 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2001-06-30 | 11 | 11 | 271.112 | |
| 2002-06-30 | 409 | 61 | 6,720.978 | |
| 2003-06-30 | 448 | 72 | 6,554.445 | |
| 2004-06-30 | 1,341 | 115 | 6,322.821 | |
| 2005-06-30 | 848 | 200 | 7,114.072 | |
| 2006-06-30 | 408 | 321 | 5,947.263 | |
| 2007-06-30 | -3.408 | 188 | -3.408 | 5,598.331 |
| 2008-06-30 | 6,399 | 92 | 6,399 | 7,519.967 |
| 2009-06-30 | 255 | 194 | 4,599.19 | |
| 2010-06-30 | 103 | 144 | 3,871.22 | |
| 2011-06-30 | 91 | 147 | 2,435.24 | |
| 2012-06-30 | 102 | 176 | 2,860.782 | |
| 2013-06-30 | 203 | 224 | 3,761.657 | |
| 2014-06-30 | 83 | 153 | 1,070.449 | 4,255.912 |
| 2015-06-30 | 3,863.988 | 205.353 | 3,863.988 | 3,888.911 |
| 2016-06-30 | 1,000 | 311.501 | 1,000 | 4,072.403 |
| 2017-06-30 | 69.115 | 202.924 | 69.115 | 3,286.722 |
| 2018-06-30 | 25.55 | 210.316 | 62.108 | 2,620.143 |
| 2019-06-30 | 66.17 | 137.761 | 449.027 | 3,583.136 |
| 2020-06-30 | 30.53 | 6,666.293 | ||
| 2021-06-30 | 4.18 | 8,683.281 | ||
| 2022-06-30 | 34.18 | 7,611.229 | ||
| 2023-06-30 | 384.92 | 13,344.975 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2001-06-30 | 13,675.341 | 20,088.222 | 54.46 | 20,427.501 | ||
| 2002-06-30 | 9,373.05 | 15,334.216 | 1,852.504 | 19,470.572 | ||
| 2003-06-30 | 6,545.567 | 11,982.149 | 364.403 | 23,714.504 | ||
| 2004-06-30 | 14,421.232 | 18,151.131 | 1,018.148 | 33,839.365 | ||
| 2005-06-30 | 8,821.132 | 11,222.068 | 357.724 | 33,836.565 | ||
| 2006-06-30 | 8,239.33 | 9,116.265 | 323.029 | 37,214.839 | ||
| 2007-06-30 | 7,596.588 | 8,049.769 | 2,032.393 | 39,263.36 | ||
| 2008-06-30 | 6,361.656 | 9,865.525 | 3,530.879 | 41,434.449 | ||
| 2009-06-30 | 3,075.717 | 4,989.23 | 1,061.728 | 41,434.449 | ||
| 2010-06-30 | 1,725.878 | 1,815.525 | 471.426 | 42,194.058 | ||
| 2011-06-30 | 2,338.356 | 2,435.861 | 417.739 | 44,673.775 | ||
| 2012-06-30 | 4,967.523 | 5,689.132 | 423.288 | 49,722.775 | ||
| 2013-06-30 | 3,999.814 | 5,201.156 | 554.101 | 51,783.828 | ||
| 2014-06-30 | 1,334.513 | 2,656.021 | 569.13 | 50 | 52,416.936 | |
| 2015-06-30 | 6,829.605 | 7,673.038 | 581.44 | 56,714.725 | ||
| 2016-06-30 | 4,800.718 | 5,327.359 | 750.204 | 56,714.725 | ||
| 2017-06-30 | 1,901.988 | 2,539.075 | 685.652 | 0 | 57,706.647 | |
| 2018-06-30 | 1,899.059 | 4,802.131 | 580.86 | 2,400 | 62,405.51 | |
| 2019-06-30 | 2,903.542 | 3,698.53 | 888.839 | 0 | 63,938.429 | |
| 2020-06-30 | 4,059.442 | 5,352.218 | 821.229 | 112.575 | 69,147.843 | |
| 2021-06-30 | 6,020.403 | 7,000.603 | 1,273.07 | 79.443 | 77,033.694 | |
| 2022-06-30 | 19,233.183 | 22,436.658 | 1,295.219 | 94.091 | 98,134.995 | |
| 2023-06-30 | 10,967.259 | 12,843.028 | 2,867.363 | 94.078 | 98,262.795 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2001-06-30 | -393.739 | 635.341 | ||||
| 2002-06-30 | -6,321.006 | -4,058.213 | 8,737.709 | 635.341 | 9,373.05 | |
| 2003-06-30 | -6,107.898 | -2,827.483 | 9,373.05 | 6,545.567 | ||
| 2004-06-30 | -4,609.624 | -2,209.608 | 7,875.665 | 6,545.567 | 14,421.232 | |
| 2005-06-30 | -6,265.839 | -5,585.305 | -5,600.1 | 14,421.232 | 8,821.132 | |
| 2006-06-30 | -5,462.401 | -3,958.499 | -581.802 | 8,821.132 | 8,239.33 | |
| 2007-06-30 | -4,835.963 | -2,679.528 | -642.742 | 8,239.33 | 7,596.588 | |
| 2008-06-30 | -2,136.886 | -3,401.498 | -1,234.932 | 7,596.588 | 6,361.656 | |
| 2009-06-30 | -2,649.727 | -3,283.821 | -3,285.939 | 6,361.656 | 3,075.717 | |
| 2010-06-30 | -3,424.875 | -1,336.627 | -1,349.839 | 3,075.717 | 1,725.878 | |
| 2011-06-30 | -1,813.55 | -1,867.239 | 612.478 | 1,725.878 | 2,338.356 | |
| 2012-06-30 | -1,801.278 | -2,405.2 | 2,629.167 | 2,338.356 | 4,967.523 | |
| 2013-06-30 | -2,454.842 | -2,833.186 | -967.709 | 4,967.523 | 3,999.814 | |
| 2014-06-30 | -3,013.272 | -3,107.886 | -2,665.301 | 3,999.814 | 1,334.513 | |
| 2015-06-30 | 706.918 | 1,268.875 | 5,495.092 | 1,334.513 | 6,829.605 | |
| 2016-06-30 | -2,514.443 | -2,025.026 | -2,028.887 | 6,829.605 | 4,800.718 | 0 |
| 2017-06-30 | -2,754.799 | -2,914.222 | -2,898.73 | 4,800.718 | 1,901.988 | 0 |
| 2018-06-30 | -2,331.015 | -2,301.793 | -2.929 | 1,901.988 | 1,899.059 | |
| 2019-06-30 | -2,944.499 | -2,928.436 | 1,004.483 | 1,899.059 | 2,903.542 | |
| 2020-06-30 | -5,908.202 | -3,945.358 | 1,155.9 | 2,903.542 | 4,059.442 | |
| 2021-06-30 | -8,060.639 | -5,834.156 | 1,960.961 | 4,059.442 | 6,020.403 | |
| 2022-06-30 | -5,834.08 | -5,744.862 | 13,212.78 | 6,020.403 | 19,233.183 | |
| 2023-06-30 | -11,379.828 | -8,151.33 | -8,265.924 | 19,233.183 | 10,967.259 |